Embark Biotech

Copenhagen, Denmark Founded: 2017 • Age: 9 yrs Acquired By Novo Nordisk
Novel therapeutics for metabolic diseases and obesity are developed.

About Embark Biotech

Embark Biotech is a Healthcare company based in Copenhagen (Denmark) founded in 2017 by Thue Schwartz, and was acquired by Novo Nordisk in August 2023. Novel therapeutics for metabolic diseases and obesity are developed. The company has 3 employees. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Obesity. Its legal entity is Embark Biotech ApS.

Company details

Embark Biotech was founded in 2017 in Copenhagen, Denmark, within the biotechnology sector. Focus is placed on developing therapeutics to address metabolic diseases and obesity. Operations center on innovative products, including EMB1, a peptide targeted at hyperphagia, and EMB2, a small molecule designed for obesity treatment. Research and development activities are conducted to advance these solutions for clinical applications.

  • Headquarters Copenhagen, Denmark
  • Employees 3
  • Founders Thue Schwartz
  • Stage Acquired
  • Sectors
    Healthcare
  • Email
    β€’β€’β€’β€’β€’β€’β€’β€’
  • Website embarkbiotech.com
  • Social LinkedIn
  • Acquired by Novo Nordisk (Aug 2023)
  • Legal Name Embark Biotech Aps
Key Metrics

Investors in Embark Biotech

Embark Biotech has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include Novo Nordisk.

All
Institutional
InvestorDescriptionFounded YearDomainLocation
Drugs for diabetes, obesity, hemophilia, and hormone therapy are manufactured.
1923novonordisk.comBagsvaerd, Denmark
Premium access

Investor details for Embark Biotech

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of Embark Biotech

1 people are tracked at Embark Biotech (1 in leadership); the tracked headcount is 3.

NameRoleGroup
Thue Schwartz
Co-FounderLeadership
Premium access

Complete people profiles for Embark Biotech

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

Timeline of Embark Biotech

2 dated milestones of Embark Biotech across 6 years, from founding to its latest funding, stage changes and deals.

  1. Founded Embark Biotech is founded.
  2. Exit Acquired by Novo Nordisk.
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track β€” from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • βœ“
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • βœ“
    Full access to every database India & global coverage, advanced filters and rich profile details
  • βœ“
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Embark Biotech

Premium access

Complete news archive for Embark Biotech

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Embark Biotech

Embark Biotech was founded in 2017.

Embark Biotech is headquartered in Copenhagen, Denmark.

Embark Biotech has 3 employees.

Embark Biotech was founded in 2017 in Copenhagen, Denmark, within the biotechnology sector. Focus is placed on developing therapeutics to address metabolic diseases and obesity. Operations center on innovative products, including EMB1, a peptide targeted at hyperphagia, and EMB2, a small molecule designed for obesity treatment. Research and development activities are conducted to advance these solutions for clinical applications.

Embark Biotech has 1 investor. Key investors include Novo Nordisk.

Embark Biotech operates through Embark Biotech Aps.

Yes. Embark Biotech was acquired by Novo Nordisk in August 2023.

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available